Aria Pharmaceuticals, Inc.

UCB and Biogen reported encouraging topline findings from the Phase III PHOENYCS GO trial, which assessed dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in individuals with moderate-to-severe SLE. The promising outcomes with dapirolizumab pegol signify significant advancements in creating treatments that can enhance the quality of life for individuals with lupus, a condition that continues to have considerable unmet medical needs, particularly impacting women. LAS VEGAS, Oct. 7, 2024 /PRNewswire/ -- Systemic lupus erythematosus is a long-lasting autoimmune disorder that can impact various areas of the body. Lupus arises when the immune system, typically responsible for defending against infections and illnesses, mistakenly targets the body's own tissues. This misguided response leads to inflammation and, in some instances, lasting damage to tissues, potentially affecting a wide range of organs including the skin, joints, heart, lungs, kidneys, blood cells, and brain. As per the estimates, the prevalence of systemic lupus erythematosus in the United States is approximately 500K cases in 2023. In females, prevalence rates are observed to be much greater than that of males, constituting more than 90% of the total prevalent cases in the US. In 2023, among the treated SLE patients, nearly 40% of patients became relapsed or refractory after the first line of therapy. The main goals of SLE treatment are to alleviate symptoms, prevent or reduce organ damage and disease flare-ups, minimize drug toxicity, and improve the patient's overall quality of life. The SLE treatment plan primarily includes antimalarial medications (like hydroxychloroquine), glucocorticoids (such as prednisone or similar), immunosuppressive drugs (including methotrexate, azathioprine, or mycophenolate), and biologics, in addition to nonsteroidal anti-inflammatory drugs (NSAIDs) for managing inflammation and pain. Biologics are specifically used for patients who do not respond to standard treatments or for those with severe, organ-threatening diseases. Currently, the biologics approved by the US FDA as adjunct therapies for SLE patients are BENLYSTA and SAPHNELO. In contrast, the use of rituximab for treating SLE is considered off-label. Learn more about the FDA-approved SLE drugs @ Drugs for Systemic Lupus Erythematosus Treatment BENLYSTA (belimumab) is a fully human monoclonal antibody that targets and inhibits BLyS (B-lymphocyte stimulator), a protein found at elevated levels in patients with systemic autoimmune diseases such as systemic lupus erythematosus and lupus nephritis. By binding to soluble BLyS, BENLYSTA prevents the prolonged survival of B cells, including autoreactive B cells, and reduces their differentiation into plasma cells that produce immunoglobulins. However, BENLYSTA does not directly bind to B cells. First approved by the US FDA in 2011, it is the only biologic therapy approved for the treatment of active SLE and LN in more than 50 years, including for pediatric patients. SAPHNELO (anifrolumab) is a fully human monoclonal antibody and the first of its kind, targeting subunit 1 of the type I interferon (IFN) receptor to inhibit type I IFN activity. Type I IFNs, including IFN-alpha, IFN-beta, and IFN-kappa, are cytokines that play a role in the inflammatory pathways associated with systemic lupus erythematosus. Most adults with SLE exhibit increased type I IFN signaling, which correlates with greater disease activity and severity. SAPHNELO has been approved for the treatment of SLE in over 60 countries, including the US, EU, and Japan, with ongoing reviews in additional regions. To know more about SLE treatment options, visit @ New Treatment for Systemic Lupus Erythematosus SLE pipeline possesses some drugs in mid and late-stage developments to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Litifilimab (Biogen), Ianalumab (Novartis), Cenerimod (Idorsia/Viatris), Dapirolizumab pegol (UCB/Biogen), Telitacicept (RC18) (RemeGen), and others in different lines of treatment. The expected launch of these therapies shall further create a positive impact on the market. Discover which therapies are expected to grab major SLE market share @ Systemic Lupus Erythematosus Market Report Dapirolizumab pegol is a novel investigational treatment, consisting of a humanized, Fc-free antigen-binding (Fab') fragment conjugated with polyethylene glycol (PEG). It works by inhibiting CD40L signaling, which has been shown to reduce B cell activation, decrease autoantibody production, limit type 1 interferon (IFN) secretion, and suppress the activation of T cells and antigen-presenting cells (APCs). In September 2024, UCB and Biogen announced that the Phase III PHOENYCS GO trial achieved its primary goal, showing clinical improvements in patients with moderate-to-severe systemic lupus erythematosus. Additionally, key secondary endpoints, assessing disease activity and flare-ups, also demonstrated clinical improvements. Following the positive results from the PHOENYCS GO study, UCB and Biogen are launching a second Phase 3 trial of dapirolizumab pegol in 2024, named PHOENYCS FLY. Participants from the PHOENYCS GO study will continue to be monitored in a long-term open-label extension. Biogen is working on developing Litifilimab (BIIB059), an experimental humanized monoclonal antibody. This antibody specifically targets and binds to blood dendritic cell antigen 2 (BDCA2), a receptor found on plasmacytoid dendritic cells (pDCs). When BDCA2 is engaged, it inhibits the production of type I interferons (IFN-I) and other inflammatory molecules. BDCA2 is exclusively expressed on the surface of human pDCs. Litifilimab acts as an inhibitor of B-cell lymphocyte stimulator. Currently, Biogen is conducting Phase III clinical trials to evaluate its use for treating SLE. Ianalumab, developed by Novartis, is an antibody aimed at the B-cell activating factor receptor (BAFF-R). It is designed to inhibit BAFF-R signaling and deplete B cells through antibody-dependent cellular cytotoxicity. The drug is currently undergoing a Phase III clinical trial for systemic lupus erythematosus, with the company expecting to submit it for approval by 2027, according to a recent presentation. Cenerimod is an oral, once-daily tablet that acts as a highly selective modulator of the sphingosine-1-phosphate receptor 1 (S1P1). Although the exact cause of systemic lupus erythematosus is not fully understood, T and B lymphocytes are believed to be the primary immune cells involved in the disease's progression. These cells express the S1P1 receptor on their surface. In February 2024, Idorsia Pharmaceuticals formed a major global research and development partnership with Viatris to advance and commercialize two Phase III assets, selatogrel and cenerimod, on a global scale. Discover more about drugs for SLE in development @ Systemic Lupus Erythematosus Clinical Trials The anticipated launch of these emerging therapies for SLE are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SLE market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for SLE is expected to grow from USD 3.2 billion in 2023 with a significant CAGR by 2034. This growth is mainly driven by ongoing clinical research and better diagnostic tools that might improve the prognosis of the disease. DelveInsight's latest published market report titled as Systemic Lupus Erythematosus Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the SLE country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The SLE market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total SLE Diagnosed Prevalent Cases Total SLE Diagnosed Prevalent Cases by Gender Total SLE Diagnosed Prevalent Cases by Age SLE Severity-Based Diagnosed Prevalent Cases Total SLE Treated Cases The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM SLE market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this SLE market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the SLE market. Also, stay abreast of the mitigating factors to improve your market position in the SLE therapeutic space. Related Reports Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. Systemic Lupus Erythematosus Epidemiology Systemic Lupus Erythematosus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted SLE epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, NOVARTIS, CABALETTA BIO, among others. Lupus Nephritis Pipeline Lupus Nephritis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including Inflection Biosciences, Equillium, Roche, Horizon Therapeutics, BeiGene, Janssen Research & Development, ImmPACT Bio, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN, Feb. 27, 2024 /PRNewswire/ -- The "Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead Generation, Optimization), Drug Design (Small Molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The artificial intelligence (AI) in drug discovery market is projected to reach USD 4.9 billion by 2028 from USD 900 million in 2023, at a CAGR of 40.2% Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market. In 2022, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America hosts numerous pharmaceutical giants and biotechnology innovators that are actively exploring AI's capabilities in drug discovery. These industry leaders are investing significantly in AI-driven research and development, driving market growth. North America's well-established regulatory framework for pharmaceuticals and healthcare facilitates the integration of AI technologies while ensuring compliance with industry standards and guidelines. The above-mentioned factors will drive the market of AI in drug discovery in North America. AI expedites the identification and validation of potential drug targets by analyzing intricate biological data. This accelerates the selection of biologically relevant targets for therapeutic interventions. AI techniques such as machine learning enable rapid analysis and decision-making, reducing the time and resources required for drug discovery processes. This efficiency gains a competitive edge in the fast-paced pharmaceutical landscape. Therefore, aforementioned factors will drive the growth of this market. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth to a certain extent over the forecast period. Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period. Based on offering, the AI in drug discovery market is bifurcated into software and services. The 2022 and segment expected to account for the largest market share of the global AI in drug discovery services market in 2022 and expected to grow fastest CAGR during the forecast period. Access to AI technology and expertise through services reduces the barriers for pharmaceutical companies to adopt AI in drug discovery. This is particularly beneficial for smaller companies without extensive in-house AI capabilities, enabling them to harness the power of AI without significant upfront investments. Machine learning technology segment accounted for the largest share of the global AI in drug discovery market. Based on technology, the AI in drug discovery market is segmented into machine learning, natural language processing (NLP), context aware processing, and other technologies. The machine learning segment accounted for the largest share of the global market in 2022 and expected to grow at the highest CAGR during the forecast period. Machine learning enables the creation of predictive models that anticipate the behavior of potential drug candidates within the human body. This aids in identifying compounds with the highest likelihood of success, reducing the costs and time associated with unsuccessful candidates. Machine learning contributes to the development of personalized treatment strategies by analyzing patient data to predict individual responses to drugs. This facilitates tailoring treatments based on genetic, molecular, and clinical information, leading to more effective outcomes, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment. Small Molecule Design and Optimization segment expected to hold the largest share of use case segment of the market in 2022. Based on use cases, the AI in drug discovery market is divided into small molecule design and optimization, understanding disease, safety and toxicity, vaccine design and optimization, antibody and other biologics design and optimization. In 2022, the small molecule design and optimization segment accounted for the largest share of the AI in drug discovery market. AI is employed in small molecule design and optimization for two main purposes. Firstly, it aids in identifying hit-like or lead-like compounds by screening existing chemical libraries or through generative de novo design. Secondly, AI optimizes the identified hits, ensuring favorable properties like binding affinity, toxicity, and synthesis, ultimately leading to the development of more effective and safer drug candidates. These factors contribute to the development and refinement of AI algorithms tailored for drug discovery use cases. This report provides insights into the following pointers: Analysis of key drivers (growing number of cross-industry collaborations and partnerships, growing need to control drug discovery & development costs and reduce time involved in drug development, patent expiry of several drugs), restraints (shortage of AI workforce and ambiguous regulatory guidelines for medical software), opportunities (growing biotechnology industry, emerging markets, focus on developing human-aware AI systems, growth in the drugs and biologics market despite the COVID-19 pandemic), and challenges (limited availability of data sets) influencing the growth of AI in drug discovery market. Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the AI in drug discovery market. Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of AI in drug discovery solutions across regions. Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the AI in drug discovery market. Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the AI in drug discovery market. Company Profiles Key Players Nvidia Corporation Exscientia Google Benevolentai Recursion Insilico Medicine Schrodinger, Inc. Microsoft Corporation Atomwise Inc. Illumina, Inc. Numedii, Inc. Xtalpi Inc. Iktos Tempus Labs Deep Genomics, Inc. Verge Genomics Bpgbio, Inc. Benchsci Valo Health Insitro Other Players Tencent Predictive Oncology, Inc. Iqvia Inc Labcorp Celsius Therapeutics Cytoreason Owkin Cloud Pharmaceuticals Evaxion Biotech Standigm Bioage Labs Envisagenics Aria Pharmaceuticals, Inc. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

The dynamics of the cutaneous lupus erythematosus market are anticipated to change in the coming years owing to the expected launch of emerging therapies. The rising research and prevalence, along with the emergence of novel therapies, will fuel the cutaneous lupus erythematosus market during the forecast period of 2023–2032. LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- DelveInsight's Cutaneous Lupus Erythematosus Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous lupus erythematosus emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China. Key Takeaways from the Cutaneous Lupus Erythematosus Market Report As per DelveInsight analysis, the cutaneous lupus erythematosus market size in the 7MM and China was approximately USD 580 million in 2022 and it is expected to grow positively at a significant CAGR during the study period (2019–2032). As per the DelveInsight estimates, in 2022, the total diagnosed prevalent cases of cutaneous lupus erythematosus were around 1.4 million cases in the 7MM and China, which are expected to grow during the study period, i.e., 2019-2032. Globally, leading cutaneous lupus erythematosus companies such as Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others are developing novel cutaneous lupus erythematosus drugs that can be available in the cutaneous lupus erythematosus market in the coming years. Some key therapies for cutaneous lupus erythematosus treatment include Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran , and others. Discover which therapies are expected to grab the major cutaneous lupus erythematosus market share @ Cutaneous Lupus Erythematosus Market Report Cutaneous Lupus Erythematosus Overview Cutaneous lupus erythematosus (CLE) is a subtype of lupus erythematosus, an autoimmune disorder that primarily affects the skin. Cutaneous lupus erythematosus specifically targets the skin, causing a range of distinctive symptoms and manifestations. The exact cause of CLE is not fully understood, but it is believed to result from a complex interplay of genetic predisposition, environmental triggers, and immune system dysfunction. Cutaneous lupus erythematosus symptoms can vary widely and often depend on the specific subtype, which includes discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and tumid lupus erythematosus (TLE). Common symptoms include skin rashes, lesions, and sensitivity to sunlight. The characteristic butterfly-shaped rash across the cheeks and nose, known as malar rash, is often associated with lupus. Diagnosing cutaneous lupus erythematosus involves a combination of clinical evaluation, medical history assessment, and laboratory tests. Dermatologists and rheumatologists may collaborate in the diagnostic process. Skin biopsies of affected areas can reveal specific histopathological features that help differentiate CLE from other skin conditions. Blood tests, such as antinuclear antibody (ANA) testing, can also assist in confirming the diagnosis and ruling out systemic involvement. Cutaneous Lupus Erythematosus Epidemiology Segmentation As per the DelveInsight estimates, in 2022, the total tumor prevalent cases of CLE by gender were around 347K and 1.1 million cases for males and females, respectively, in the 7MM and China, which are expected to grow during the study period, i.e., 2019─2032. The cutaneous lupus erythematosus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM and China segmented into: Total Diagnosed Prevalent Cases Total Prevalent Cases of CLE by Gender Total Prevalent Cases of CLE by Type Total Treated Cases Total Prevalent Cases of CLE by Severity Cutaneous Lupus Erythematosus Treatment Market Cutaneous lupus erythematosus treatment is a nuanced process that takes into account the diverse clinical presentations and underlying immune mechanisms of the disorder. For patients with mild, localized forms of CLE, topical therapies like corticosteroid creams, calcineurin inhibitors, and retinoids can be beneficial in reducing inflammation and controlling symptoms. Antimalarial medications, such as hydroxychloroquine, are considered a cornerstone of CLE treatment due to their ability to modulate the immune response and mitigate skin manifestations. In cases of more extensive or persistent CLE, systemic treatments may be necessary. Immunosuppressive drugs like methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine can help manage the immune dysfunction that triggers skin symptoms. Biologic agents, which target specific components of the immune system, are emerging as potential options for severe or treatment-resistant cases. However, the cutaneous lupus erythematosus treatment landscape is complex and evolving. Therapeutic choices are tailored to the individual's subtype, symptom severity, and overall health. Additionally, patient education on sun protection and skin care remains a crucial aspect of CLE management, as ultraviolet light can exacerbate symptoms. Multidisciplinary collaboration between dermatologists, rheumatologists, and other healthcare providers ensures a comprehensive approach to care, addressing not only the physical symptoms but also the psychological and emotional aspects of living with a chronic autoimmune condition like CLE. Regular monitoring and adjustment of treatment plans, along with ongoing research efforts, contribute to refining the strategies for managing cutaneous lupus erythematosus. To know more about cutaneous lupus erythematosus treatment, visit @ Cutaneous Lupus Erythematosus Treatment Drugs Key Cutaneous Lupus Erythematosus Therapies and Companies Litifilimab: Biogen Daxdilimab: Horizon Therapeutics SOTYKTU (deucravacitinib): Bristol-Myers Squibb Edecesertib: Gilead Sciences DS-7011a: Daiichi Sankyo, Inc. Enpatoran: EMD Serono Learn more about the FDA-approved drugs for cutaneous lupus erythematosus @ Drugs for Cutaneous Lupus Erythematosus Treatment Cutaneous Lupus Erythematosus Market Dynamics The cutaneous lupus erythematosus market dynamics have undergone a significant transformation in recent times. This relatively understudied facet of lupus, primarily affecting the skin, has gained recognition due to heightened awareness and improved diagnostic techniques. The growing prevalence of autoimmune disorders, including CLE, has prompted pharmaceutical companies to invest in research and development endeavors targeting innovative treatment approaches. Clinicians and patients alike are advocating for therapies that not only alleviate the visible symptoms of skin involvement but also address the underlying immune dysregulation. The advent of precision medicine has fueled the exploration of targeted interventions, such as monoclonal antibodies and Janus kinase (JAK) inhibitors, tailored to counteract specific immune pathways driving CLE. These advancements, although promising, come with challenges like high development costs and the need for comprehensive clinical trials to establish efficacy and safety profiles. Additionally, the cutaneous lupus erythematosus market dynamics are influenced by the demand for non-pharmacological interventions, such as photoprotective measures and lifestyle modifications, which form an integral part of holistic CLE management. Despite increased attention, the limited understanding of CLE's intricate pathophysiology remains a significant hurdle. The complexity of immune system dysregulation specific to skin involvement presents challenges in identifying suitable drug targets and developing precise interventions. Additionally, the lack of standardized diagnostic criteria for various CLE subtypes can delay accurate diagnosis and initiation of appropriate treatment. Limited awareness and knowledge among healthcare professionals regarding CLE's diverse manifestations can lead to misdiagnosis or underdiagnosis, affecting patient access to timely and proper care. This is exacerbated by the scarcity of dedicated treatment guidelines, leading to variations in therapeutic approaches. Moreover, as the cutaneous lupus erythematosus market moves towards personalized medicine, the challenge of developing treatments that can cater to the genetic and immunological diversity of CLE patients becomes evident. Scope of the Cutaneous Lupus Erythematosus Market Report Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and emerging therapies Cutaneous Lupus Erythematosus Market Dynamics: Conjoint Analysis of Emerging Cutaneous Lupus Erythematosus Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cutaneous Lupus Erythematosus Market Access and Reimbursement Discover more about cutaneous lupus erythematosus drugs in development @ Cutaneous Lupus Erythematosus Clinical Trials Table of Contents Related Reports Cutaneous Lupus Erythematosus Pipeline Cutaneous Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cutaneous lupus erythematosus companies, including Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, among others. Cutaneous Lupus Erythematosus Epidemiology Cutaneous Lupus Erythematosus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted cutaneous lupus erythematosus epidemiology in the 7MM. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key systemic lupus erythematosus companies, including GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma, Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, among others. Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP